INDIANAPOLIS (AP) -- Eli Lilly and Co. and Amylin Pharmaceuticals Inc. lifted restrictions on their newest diabetes drug this week after a cartridge shortage forced the two companies to ask doctors to limit the number of patients they start on the regimen. The all-clear for Byetta, which began Monday, came two months after Lilly and Amylin asked 40,000 physicians to stop prescribing the drug to new patients.
